Common stock, par value $0.001 per share
- Symbol
- APRE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 3.01 · 8-K
Aprea Therapeutics, Inc.
APRENASDAQEQUITYCurrent
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, while the Company has not yet regained compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq…
Company context
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are
Current securities
Registered securities in this filing
Aprea Therapeutics, Inc. · 8-K · Filed 2026-07-23
Disclosure sections
Item 3.01Item 3.01 - Notice of Delisting
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
On July 23, 2026, Aprea
Therapeutics, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”)
informing the Company that, while the Company has not yet regained compliance with the $1.00 minimum bid price required for continued
listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”),
Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until January 19, 2027 (the “Second
Compliance Period”), to regain compliance with the Minimum Bid Price Requirement.
As previously reported, on
January 23, 2026, the Company received a deficiency notice from Nasdaq informing the Company that its common stock (the “Common
Stock”) had failed to comply with the Minimum Bid Price Requirement and, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the
Company was initially provided 180 calendar days, or until July 22, 2026, to regain compliance.
If at any time during the
Second Compliance Period, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business
days, Nasdaq will provide the Company with written confirmation of compliance. If compliance with the Minimum Bid Price Requirement cannot
be demonstrated by January 19, 2027, Nasdaq will provide written notification that the Common Stock will be delisted from Nasdaq.
At that time, the Company may appeal Nasdaq’s determination to a hearings panel.